Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;103(1):89-91.
doi: 10.1136/archdischild-2017-313404. Epub 2017 Oct 7.

Biosimilar infliximab use in paediatric IBD

Lisa Richmond  1 , Lee Curtis  1 , Victoria Garrick  1 , Pam Rogers  2 , Michelle Wilson  3 , Rachel Tayler  1 , Paul Henderson  2   3 , Richard Hansen  1 , David C Wilson  3 , Richard K Russell  1
Affiliations

Biosimilar infliximab use in paediatric IBD

Lisa Richmond et al. Arch Dis Child. 2018 Jan.

Abstract

Background: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease.

Methods: Prospective clinical data were collected from laboratory reports, electronic patient records and case notes of 40 patients starting Remsima for the first time. Disease activity scores together with blood and stool biomarkers were used to assess response.

Results: Our data set highlights that Remsima was associated with a significant clinical and biochemical improvement (p<0.01 or less for all parameters assessed) in Crohn's disease post induction. There were no significant safety issues noted. The total cost saving was £47 800, representing a 38% reduction from originator.

Conclusion: We found that biosimilar infliximab is as effective as originator infliximab and its use is associated with significant cost savings.

Keywords: biosimilars; inflammatory bowel disease; infliximab; paediatric.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LR: conference fees and travel from Tillotts. VG: conference fees and travel from AbbVie. RT: speaker’s fees and conference attendance from Nutricia. PH: lecture fees from Dr Falk. RH: speaker’s fees, conference support or consultancy fees from Nutricia, Dr Falk, MSD Immunology and 4D Pharma. DCW: lecture fees, consultancy, travel support from AbbVie; consultancy from Takeda; and financial support for research by MSD. RKR: speaker’s fees, travel support and participated in medical board meetings with AbbVie, Napp and Nestle. All other listed authors have no declared conflicts of interest.

Figures

Figure 1
Figure 1
Infliximab levels at week 14 following induction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cameron FL, Wilson ML, Basheer N, et al. . Anti-TNF therapy for paediatric IBD: the Scottish national experience. Arch Dis Child 2015;100:399–405. 10.1136/archdischild-2013-305812 - DOI - PubMed
    1. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012;18:985–1002. 10.1002/ibd.21871 - DOI - PubMed
    1. Turner D, Griffiths AM, Walters TD, et al. . Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012;18:55–62. 10.1002/ibd.21649 - DOI - PubMed
    1. Turner D, Otley AR, Mack D, et al. . Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423–32. 10.1053/j.gastro.2007.05.029 - DOI - PubMed
    1. Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. . Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. preliminary observations. J Crohns Colitis 2016;10:127–32. 10.1093/ecco-jcc/jjv233 - DOI - PubMed

Publication types